Date: 2017-07-12
Type of information: Nomination
Compound: non-executive director
Company: Enterome Bioscience (France)
Therapeutic area: Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 12, 2017, Enterome announced that Mary Thistle has joined the Enterome board as a Non-executive Director. Ms. Thistle is currently chief operating officer at Dimension Therapeutics, a biopharmaceutical company discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology.
- Prior to joining Dimension in 2015, Ms. Thistle was Senior Vice President, Business Development at Cubist Pharmaceuticals, where she was responsible for four major acquisitions, including Trius Therapeutics and Optimer Pharmaceuticals, significantly driving growth of the company’s pipeline prior to Cubist’s $9.5 billion acquisition by Merck & Co. Prior to this, she held leadership positions at ViaCell. Ms. Thistle began her career in finance as a certified public accountant working with both private and public companies. She received her B.A. degree in accounting from the University of Massachusetts.
Financial terms:
Latest news:
Is general: Yes
